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Abstract
Introduction Patient adherence to therapy in clinical practice is
often low, and the difference between efficacy measured in
clinical trials and effectiveness in clinical practice is probably a
function of discontinuation of therapy because of lack of efficacy
or because of unmanageable or intolerable adverse events.
Discontinuation is frequently measured in clinical trials but is not
usually described in detail in published reports, often because of
limitations in the size of publications. By contrast, company
clinical trial reports include much more detail.
Methods We examined company clinical trial reports of trials
involving etoricoxib in four musculoskeletal conditions:
osteoarthritis, rheumatoid arthritis, chronic low back pain and
ankylosing spondylitis. Information was available from 18
randomized trials (10,143 patients) lasting 4 to 12 weeks (one
4 weeks, three 6 weeks, one 8 weeks and seven 12 weeks) and
from three trials with a mean duration of about 80 weeks
(34,695 patients). These clinical trial reports contain over
73,000 pages of information.
Results Over 12 weeks, lack of efficacy and adverse event
discontinuations were similar between osteoarthritis,
rheumatoid arthritis and back pain, with lack of efficacy
discontinuation rates some three times higher than for adverse
events. All-cause and lack of efficacy discontinuations were
lower with etoricoxib (all doses combined) and traditional
nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)
than with placebo, although NSAIDs produced higher rates of
clinical adverse events and gastrointestinal discontinuations
than did placebo. Etoricoxib had fewer discontinuations than
NSAIDs for lack of efficacy, clinical adverse events, and
laboratory and gastrointestinal adverse events, but with more
discontinuations because of hypertension and oedema.
Comparison with two similar meta-analyses of other cyclo-
oxygenase-2 selective inhibitors (more than 80,000 patients in
total) revealed consistency between analyses.
Conclusion Examining discontinuation data from clinical trials,
even when the numbers of patients are very large, does not
necessarily predict what will happen in the real world, where
clinical effectiveness may differ from clinical efficacy assessed in
trials. Data from these analyses appears to agree with findings
from real world practice.
Introduction
Clinical trials most often measure efficacy – the ability of an
intervention to produce the desired result. They tend not to
measure effectiveness, which are the actual results found in
clinical practice – a product of efficacy and adherence to ther-
apy. The difference between trial efficacy and clinical effective-
ness can be ascribed to the tendency of patients not to adhere
to therapy, especially in the longer term. Discontinuation of
therapy is most often due to lack of efficacy or unmanageable
or intolerable adverse events, or both.
Patient adherence to therapy is known to be low, especially
where therapy is prophylactic or does not deliver rapid symp-
tomatic relief. In the USA it is estimated that only about 50%
of patients continue statin therapy at 6 months, and 30% to
40% at 1 year [1]. In the UK 50% of patients prescribed low-
dose aspirin have discontinued within a year [2]. Where ben-
efit is greater and more tangible, adherence is likely to be
higher, even if adverse events are common. Thus, among renal
transplant patients, only 15% were found to be nonadherent
to immunosuppressants using stringent criteria [3].
coxib = cyclo-oxygenase-2 inhibitor; NNH = number needed to treat to cause an event; NNTp = number needed to treat to prevent an event; NSAID 
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Adverse events are a major concern to patients. A Dutch study
[4] found that half of 232 chronic prescriptions for long-term
medicines were not refilled over 3 months, with adverse events
being a major reason. Talking to patients about adverse events
can help, but it may well depend on how the adverse event
rates are described. In a randomized trial conducted in 120
patients given information about the adverse events associ-
ated with the medicine [5], it was found that the patients were
more likely to be compliant, and had less fear, when they were
presented with information about adverse events in percent-
age terms rather than in words.
Physician adherence to guidelines is also known to be low.
Prescribing of nonsteroidal anti-inflammatory drug (NSAID)
plus gastroprotective agent or cyclo-oxygenase-2 inhibitor
(coxib) was identified in only 26% of patients with at least one
gastrointestinal risk factor in a large systematic review of stud-
ies published since 2000 [6]. More or better professional edu-
cation can improve matters, as with antihypertensive
prescribing in Canada [7,8].
Few patients appear able to take oral NSAIDs prescribed for
chronic musculoskeletal problems for a long time. For
instance, only 15% to 20% of those started on a study NSAID
were still using the same drug at the end of 12 months in an
observational study conducted in Seattle [9], whereas in a tel-
ephone survey [10], also conducted in the USA, drug contin-
uation beyond 24 months was reported by 33% of patients for
paracetamol (acetaminophen), 21% for ibuprofen, 17% for
naproxen and 19% for diclofenac. Most studies are too small
to measure differences in continuation rates between NSAIDs
adequately, although recent larger studies have consistently
observed longer continuation rates for coxibs over traditional
nonselective NSAIDs [11,12].
Company clinical trial reports do not suffer from the problems
of selective reporting in published papers that results from
strict word limitations. Although efficacy in published studies
has in the past been poorly presented [13], adverse event
information is even more poorly presented in published papers
[14]. Both, but particularly adverse events, may be more
clearly presented in company clinical trial reports. Company
clinical trial reports potentially provide an ideal source of infor-
mation for systematic review and meta-analysis, particularly on
discontinuation rates for different causes [15,16].
Meta-analysis of discontinuation rates in randomized trials of
drug therapy has been undertaken infrequently. In psychiatry,
studies in schizophrenia [17] and depression [18,19] have
sought to differentiate drugs by discontinuation rates, as have
studies in Helicobacter treatment [20] or hypertension [21].
Discontinuation rates have been included in previous meta-
analyses of clinical trials of analgesics in musculoskeletal pain
[15,16].
In this report we examine discontinuation rates in randomized
trials of etoricoxib in chronic musculoskeletal conditions. Our
prior hypotheses were as follows. First, discontinuation rates
would differ between osteoarthritis (OA), rheumatoid arthritis
(RA) and other musculoskeletal conditions for lack of efficacy,
but probably not because of adverse events. Second, discon-
tinuation rates would differ between shorter and longer trials.
Third, discontinuations because of gastrointestinal adverse
events would be lower with etoricoxib than with traditional
NSAIDs. Finally, higher doses of etoricoxib would produce
lower rates of lack of efficacy discontinuations and higher
rates of adverse event discontinuations.
Materials and methods
The data for this meta-analysis were contained in clinical trial
reports of 18 randomized trials of etoricoxib lasting 4 to 12
weeks, and three trials with mean duration of more than 1 year.
Merck Research Laboratories (Rahway, NJ, USA) provided
clinical trial reports in the form of PDF (19 trials) or Word (two
trials) documents. No additional literature searching was
conducted.
Information from the clinical trial reports was tabulated, includ-
ing diagnosis and trial entry criteria, demographic information,
drugs, dose and duration of treatment. Patients who were ran-
domized and received at least one dose of drug were consid-
ered the intention-to-treat population. Also extracted were the
following outcomes: all-cause discontinuations; discontinua-
tions due to lack of efficacy; discontinuations due to a clinical
adverse event; discontinuations due to a laboratory adverse
event (hepatic, renal, or haematological); and discontinuations
for specific reasons, namely gastrointestinal adverse event,
oedema, hypertension, or a serious adverse event.
In addition, information about the time course of discontinua-
tions was sought. Where this information was in graphical
form, printed versions were used to calculate the number of
patients remaining after discontinuation for lack of efficacy or
adverse event. Extrapolation was not done where the scale of
graphs precluded accurate estimation.
The nomenclature for discontinuation does not appear to be
fixed. Although discontinuations for a particular cause might
be described as a percentage of the total (100x/n, where x is
the number discontinued and n the total number of patients),
it is common for discontinuations to be described as a contin-
uation (100 - 100x/n) to produce a description of survival on
treatment. This has previously been done for NSAIDs [9], and
we chose to follow this example to describe discontinuation
over the first 12 weeks of treatment.
Trial reporting quality and validity were examined using two
Oxford scales [22,23]. Relative risk with 95% confidence
interval was calculated using the fixed effects model [24], and
was considered to be statistically significant when the 95%Available online http://arthritis-research.com/content/10/3/R53
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confidence interval did not include 1. We calculated the
number needed to treat to prevent an event (NNTp) or cause
an event (NNH), with a 95% confidence interval, from the sum
of all events and patients for treatment and placebo groups
[25]. Heterogeneity tests were not used because they have
previously been shown to be unhelpful, although homogeneity
was examined visually [26,27]. Publication bias was not
assessed using funnel plots because these tests have been
shown to be unhelpful [28,29]. QUOROM (Quality Of Report-
ing Of Meta-analyses) guidelines were followed where appro-
priate [30].
Results
Trials
Information was available for 18 randomized trials (10,143
patients) lasting 4 to 12 weeks (one 4 weeks, three 6 weeks,
one 8 weeks and seven 12 weeks) and three trials (34,695
patients) with a mean duration about 80 weeks. These clinical
trial reports contained over 73,000 pages of information,
mainly in the form of PDF documents. These were comprehen-
sive documents detailing methods and results, with many
tables and figures. Five trials were conducted completely or
mainly in patients with RA, 12 completely or mainly in patients
with OA, three in chronic low back pain, and one in ankylosing
spondyitis. Details of trials and outcomes are presented in
Additional file 1. All trials scored 5 out of 5 on a validated qual-
ity scale and 16 out of 16 on a validity scoring scale.
Sixteen of the 4-week to 12-week trials included a placebo
control group (2,336 patients receiving placebo), in which up
to two 325 mg tablets of paracetamol (acetaminophen) were
allowed as rescue medication to a maximum of four times a
day for short periods. Phase III and IV trials studied daily doses
of etoricoxib of 30 mg and 60 mg in OA patients; the 90 mg
daily dose, representing 1.5 times the maximum recom-
mended daily dose, was also studied in OA patients in two tri-
als (061 EDGE and 066 MEDAL trials). The daily dose of 90
mg was assessed in patients with RA. Daily doses of 60 mg
and 90 mg (1.5 times the maximum recommended daily dose)
were assessed in patients with chronic low back pain; daily
doses of 90 mg and 120 mg (1.33 times the maximum recom-
mended daily dose) were assessed in patients with ankylosing
spondylitis. The comparator cyclo-oxygenase-2 selective
inhibitor was celecoxib 200 mg or 400 mg daily. Comparator
NSAIDs were naproxen 1,000 mg daily, diclofenac 150 mg
daily and ibuprofen 2,400 mg daily; diclofenac was used pre-
dominantly in longer duration studies, and naproxen was the
predominant comparator in studies of 12 weeks or less.
Celecoxib was used in three trials, one comparing celecoxib
400 mg with etoricoxib 90 mg in OA, and two comparing
celecoxib 200 mg with etoricoxib 30 mg in OA (Additional file
1). Given the relatively small numbers of patients available, no
comparisons were performed on celecoxib data either with
placebo or with etoricoxib; with celecoxib there was only about
10% of the number of patients available for NSAID versus pla-
cebo, for example.
In OA and RA trials the majority of patients (usually ≥ 70%)
were women, and the mean age in the trial was over 60 years.
In trials of low back pain, women comprised about 60% of
patients, and the mean age was about 50 years. In the trial of
ankylosing spondylitis only 20% of patents were women, and
the mean age was 44 years. Patients were preponderantly
white in all but one trial. One trial (066 MEDAL trial) reported
separate data for OA for 60 and 90 mg doses of etoricoxib,
and for RA; these separate reporting groups were used in any
analysis.
Discontinuation with placebo over 12 weeks
Additional files 2 and 3 contain the rates of discontinuation
over 12 weeks for any cause and because of lack of efficacy
or because of an adverse event, according to whether patients
were given placebo or active therapy. Figure 1 shows that dis-
continuation because of lack of efficacy with placebo tended
to be higher in patients with RA than in those with OA or back
pain, to the extent of about 10% after 12 weeks. Figure 1 also
shows that discontinuation because of adverse events with
placebo was not different in patients with different conditions.
Overall discontinuation because of lack of efficacy with pla-
cebo at 12 weeks was 24%, some three times higher than the
percentage of discontinuations because of adverse events.
Discontinuation with active drug over 12 weeks
With active drugs, discontinuation because of lack of efficacy
was noticeably less than placebo, with small differences
between OA and RA (Figure 2). In OA trials lack of efficacy
discontinuation rates at 12 weeks ranged between 4% and
13% for individual drugs and doses, as compared with 19%
with placebo. In RA trials discontinuation rates at 12 weeks
ranged between 6% and 18% for individual drugs and doses,
as compared with 30% with placebo.
With active drugs, discontinuation because of adverse events
was not noticeably different from that with placebo, with small
differences between OA and RA (Figure 3). In OA trials dis-
continuation rates at 12 weeks ranged between 4% and 11%
for individual drugs and doses, as compared with 7% with pla-
cebo. In RA trials discontinuation rates at 12 weeks ranged
between 4% and 6% for individual drugs and doses, as com-
pared with 6% with placebo.
For lack of efficacy discontinuation there was an appreciable
dose-response relation for etoricoxib over the range of 30 mg
to 120 mg daily for OA and RA (Table 1). For adverse event
discontinuation there was no appreciable dose-response rela-
tion. For no other condition were there sufficient numbers of
trials, patients and doses to make any sensible comparison.Arthritis Research & Therapy    Vol 10 No 3    Moore et al.
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Etoricoxib discontinuations compared with placebo and 
active comparators
Table 2 shows the outcomes of patient discontinuations from
any cause, because of lack of efficacy, a clinical adverse event,
a laboratory adverse event, a gastrointestinal adverse event,
serious adverse event, or because of hypertension or oedema.
All doses of etoricoxib combined were compared with pla-
cebo, and with traditional NSAIDs combined, in trials lasting 4
to 12 weeks, and in all trials combined. These analyses did not
include celecoxib as a comparator.
Etoricoxib and NSAIDs had lower rates of all-cause discontin-
uation than did placebo (NNTp 6.7 and 19, respectively). Etor-
icoxib had lower all-cause discontinuations rates than did
NSAIDs in studies conducted over 4 to 12 weeks and in those
of longer duration (NNTp 16 and 31, respectively). This result
was largely driven by lack of efficacy discontinuation, which for
placebo constitutes 72% of all discontinuations. Thus, etori-
coxib and NSAIDs had lower rates of lack of efficacy discon-
tinuation than did placebo (NNTp 7.4 and 6.6, respectively).
Etoricoxib had a lower all-cause discontinuation rate than did
NSAIDs in all trials (NNTp 31).
For clinical adverse event discontinuation, NSAIDs were asso-
ciated with a significantly higher rate than placebo (NNH 23),
whereas etoricoxib had significantly fewer clinical adverse
event discontinuations than did placebo in studies conducted
over 4 to 12 weeks (NNTp 31) but not in trials of longer dura-
tion. For laboratory adverse event discontinuations, etoricoxib
was associated with significantly fewer than was NSAIDs in tri-
als of longer duration (NNTp 49), with laboratory adverse
Figure 1
Lack of efficacy or adverse event discontinuation: placebo Lack of efficacy or adverse event discontinuation: placebo. Shown are the percentages of patients remaining in the studies conducted over 4 to 12 
weeks with placebo after withdrawal because of lack of efficacy (LoE) or an adverse event (AE). CLBP, chronic low back pain; OA, osteoarthritis; 
RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/10/3/R53
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event discontinuations driven largely by elevated liver enzymes
with diclofenac, which is the only NSAID used in the longer
duration trials.
Gastrointestinal adverse event discontinuations were not dif-
ferent between etoricoxib and placebo in trials conducted over
4 to 12 weeks, but they were significantly higher with NSAIDs
than with placebo over the same period (NNH 33). Etoricoxib
at all doses was associated with significantly fewer gastroin-
testinal adverse event discontinuations than was NSAIDs in
shorter and longer trials (NNTp 47 and 30, respectively).
Although the difference between etoricoxib and NSAID
tended to be consistent across studies of different duration
and size (Figure 4), it was most marked in studies of longer
duration.
There was no difference in any comparison for discontinua-
tions because of serious adverse events. Discontinuations
because of hypertension and oedema occurred more fre-
quently with etoricoxib than with NSAIDs in trials of longer
duration (NNH 120 and 320, respectively).
Discussion
This analysis demonstrated again that useful and informative
information can be obtained from clinical trial reports, which
are more detailed in their reporting of the trials than are pub-
lished papers, if only because they are not constrained by dic-
tates of size. Here, for instance, information from almost
45,000 patients was contained in just over 73,000 pages –
close to two pages per patient. This allows for more detail, and
the combination of more detail and large numbers of patients
offers the possibility of greater insight. This has been seen pre-
viously for valdecoxib [15] and celecoxib [16] in arthritis, for
efficacy outcomes in acute pain [31,32] and for adverse
events for contraceptives [33].
In this case it was possible to examine discontinuation rates
and causes in some detail over the first 12 weeks of treatment.
With placebo there were slight differences for lack of efficacy
Figure 2
Lack of efficacy discontinuation: placebo, etoricoxib, and individual NSAIDs Lack of efficacy discontinuation: placebo, etoricoxib, and individual NSAIDs. Shown are the percentages of patients remaining after lack of efficacy 
(LoE) discontinuation in studies conducted over 4 to 12 weeks with placebo, etoricoxib, and individual nonsteroidal anti-inflammatory drugs 
(NSAIDs). OA, osteoarthritis; RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 10 No 3    Moore et al.
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discontinuation between conditions, with slightly higher rates
for RA over OA, but no difference between conditions for
adverse event withdrawals (Figure 1). As would be expected,
for placebo lack of efficacy withdrawal at 12 weeks was at
least three times higher than was adverse event withdrawal.
With etoricoxib and NSAIDs, lack of efficacy withdrawal was
considerably less than with placebo (Table 2 and Figure 2).
Etoricoxib was no different from placebo in terms of clinical
adverse event discontinuations, but NSAIDs were associated
with higher rates, with a NNH of 23. Etoricoxib was associated
with lower all-cause discontinuation rates than was placebo,
mainly because of fewer lack of efficacy discontinuations. Etor-
icoxib produced significantly more discontinuations for
oedema and hypertension (Table 2).
Additional file 4 shows a wider comparison of discontinuation
rates, where data from this analysis are examined alongside
data from similar analyses of valdecoxib [15] and celecoxib
[16]; information from the valdecoxib and celecoxib analyses
is recalculated where necessary to make the comparisons
similar. In total, these three analyses involve 81,664 patients
enrolled in randomized controlled trials of high quality and
validity in the settings of OA, RA, back pain, and ankylosing
spondylitis. In 41,608 patients involved in trials lasting 4 to 12
weeks, 6,581 received placebo, 502 paracetamol 4,000 mg
daily, 12,093 traditional nonselective NSAIDs at maximum
licensed daily doses, and 21,892 received a coxib within the
licensed dose range. In trials lasting 26 weeks or longer,
40,596 patients received NSAID at maximum licensed daily
doses or a coxib within the licensed dose range. We could find
no similar analyses for rofecoxib or lumiracoxib, although the
celecoxib analysis provided data on rofecoxib, and the etori-
coxib analysis provided information on celecoxib (presented
separately in Additional file 4).
This wider comparison shows a degree of consistency
between the different datasets. For instance, with placebo the
rate of lack of efficacy discontinuation is consistently about
70% of all-cause discontinuations. All-cause discontinuations
Figure 3
Clinical adverse event discontinuation: placebo, etoricoxib, and individual NSAIDs Clinical adverse event discontinuation: placebo, etoricoxib, and individual NSAIDs. Shown are the percentages of patients remaining after clinical 
adverse event (AE) discontinuation in studies conducted over 4 to 12 weeks with placebo, etoricoxib, and individual nonsteroidal anti-inflammatory 
drugs (NSAIDs). OA, osteoarthritis; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/10/3/R53
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were lower with NSAIDs (22% to 31%) and paracetamol
(25%) than with placebo (32% to 47%), and tended to be
lower still with coxibs in trials of 4 to 12 weeks (14% to 31%).
Adverse event discontinuations are similar across all treat-
ments: 4.4% to 6.3% with placebo, 5.4% with paracetamol,
5.2% to 8.5% with coxibs, and 7.4% to 11% with NSAIDs. As
expected, discontinuations because of a gastrointestinal
adverse event tended to be higher with traditional nonselective
NSAIDs than with any other treatment (Figure 5). Compari-
sons in longer duration trials are hampered by a dearth of trials
of longer duration using licensed doses of celecoxib and
valdecoxib.
Examining discontinuation data from clinical trials, even when
the numbers of patients are very large, does not necessarily
predict what will happen in the real world, where it is the clini-
cal effectiveness of therapy rather than efficacy in clinical trials
that is paramount. There are few comparisons on which to
draw, although it is generally assumed that discontinuation
rates are higher in clinical practice than in clinical trials. For
coxibs and NSAIDs, both clinical trials and observational stud-
ies [11,12] concur in their conclusion that adherence is higher
with coxibs than with NSAIDs.
Discontinuation results examined here in trials of coxibs and
NSAIDs over 12 weeks in musculoskeletal conditions can be
compared with trials of other interventions in musculoskeletal
and other chronic painful conditions. For example, lack of effi-
cacy and adverse event discontinuations with placebo in
short-term trials of opioids in nonmalignant pain were 20% and
7%, respectively [34], similar to our findings for etoricoxib
(Table 2). Similar discontinuations rates occur with placebo in
12-week trials in neuropathic pain [35]. Although lack of effi-
cacy discontinuation is typically low (≤ 7%) with active thera-
pies in these conditions, adverse event withdrawal over 12
weeks can be higher (>20% with opioids [34] and about 15%
in neuropathic pain), with NNH values for adverse event with-
drawal of the order of 10 to 15 [35]. Assessment of adherence
in randomized trials is not without its complications and meth-
odological difficulties [36], and this potentially complicates
comparisons across datasets.
Discontinuation rates in clinical trials represent important
aspects of both efficacy and harm, and deserve more atten-
tion. Here, with etoricoxib, discontinuations could be examined
in detail because large numbers of patients participated in
good quality and well recorded clinical trials, using different
doses of etoricoxib and comparators in different clinical condi-
tions. Not all new treatments, and few older ones, enjoy this
luxury in terms of the data available.
This does not prevent discontinuations from being a useful
measure, perhaps as much or more so in clinical practice as in
clinical trials, although discontinuations have been mentioned
previously in clinical trials in rheumatology, as with meloxicam
in ankylosing spondylitis [37]. In clinical practice, discontinua-
tion rates for adverse events and lack of efficacy has been
used to distinguish between disease-modifying antirheumatic
Table 1
Dose-response of etoricoxib for lack of efficacy and clinical adverse event discontinuations in osteoarthritis and rheumatoid 
arthritis trials
Dose etoriocoxib (mg) Number of patients Discontinuations (%)
Lack of efficacy Clinical adverse event
Osteoarthritis
0 974 16 5.2
30 1015 7.3 4.1
60 814 3.6 4.8
90 112 1.8 5.4
120 221 0.9 7.7
Rheumatoid arthritis
0 1,143 29 2.7
60 126 1.6 4.8
90 913 14 2.7
120 463 3.9 5.4Arthritis Research & Therapy    Vol 10 No 3    Moore et al.
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Table 2
Analysis of patients with adverse events and discontinuations
Outcome/comparisons Number of Rate of events (%) Relative risk (95% CI) NNTp/NNH (95% CI)
Trials Patients Etoricoxib Comparator
All cause
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 17 32 0.6 (0.53 to 0.63)a 6.7 (5.8 to 7.8)b
NSAID versus placebo (4 to 12 weeks) 10 3,690 26 32 0.9 (0.80 to 0.99)a 19 (13 to 31)b
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 17 22 0.7 (0.65 to 0.82)a 16 (11 to 29)b
Etoricoxib versus NSAID (all trials) 17 39,881 47 51 0.95 (0.93 to 0.97)a 31 (24 to 44)b
Lack of efficacy
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 7.2 22 0.4 (0.32 to 0.41)a 7.4 (6.3 to 8.9)b
NSAID versus placebo (4 to 12 weeks) 10 3,690 9.1 23 0.5 (0.45 to 0.62)a 6.6 (5.9 to 7.6)b
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 7.6 7.5 1.0 (0.8 to 1.2)
Etoricoxib versus NSAID (all trials) 17 39,881 8.8 9.5 0.9 (0.86 to 0.97)a 145 (80 to 820)b
Clinical adverse event
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 5.1 4.4 1.2 (0.9 to 1.4)
NSAID versus placebo (4 to 12 weeks) 10 3,690 8.2 3.8 1.8 (1.4 to 2.4)a 23 (17 to 35)c
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 5 8.2 0.7 (0.53 to 0.81)a 31 (22 to 54)b
Etoricoxib versus NSAID (all trials) 17 39,881 17 18 1.0 (0.94 to 1.02)
Laboratory adverse event
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 0.7 0.7 0.9 (0.5 to 1.7)
NSAID versus placebo (4 to 12 weeks) 10 3,690 0.7 0.6 0.9 (0.4 to 2.1)
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 0.3 0.5 0.6 (0.3 to 1.4)
Etoricoxib versus NSAID (all trials) 17 39,881 1.2 3.3 0.4 (0.34 to 0.45)a 49 (43 to 57)b
Gastrointestinal adverse event
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 1.9 1.7 1.3 (0.9 to 1.8)
NSAID versus placebo (4 to 12 weeks) 10 3,690 4.7 1.6 2.6 (1.7 to 3.9) 33 (24 to 52)c
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 2.0 4.1 0.5 (0.38 to 0.73)a 47 (33 to 85)b
Etoricoxib versus NSAID (all trials) 17 39,881 4.4 7.7 0.6 (0.54 to 0.63)a 30 (27 to 35)b
Serious adverse event
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 0.9 0.7 1.0 (0.6 to 1.7)
NSAID versus placebo (4 to 12 weeks) 10 3,690 0.9 0.6 1.2 (0.6 to 2.4)
Etoricoxib versus NSAID (4 to 12 weeks) 12 5,186 0.7 0.9 0.8 (0.5 to 1.6)
Etoricoxib versus NSAID (all trials) 17 39,881 5.5 5.3 1.1 (0.98 to 1.2)
Hypertension
Etoricoxib versus placebo (4 to 12 weeks) 16 6,388 0.4 0.04 1.6 (0.8 to 3.5)Available online http://arthritis-research.com/content/10/3/R53
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drugs [38,39]. Whether discontinuations meet all of the vari-
ous criteria of truth, discrimination and feasibility that consti-
tute all the possible subquestions in the OMERACT (Outcome
Measures in Rheumatology) filter [40] is moot. We know of no
formal evaluation, but at face value discontinuation is easy to
record, with the cause, and provides useful information.
Conclusion
This review of a large number of randomized trials and patients
provided a more detailed account of discontinuation rates in
trials of anti-inflammatory drugs in musculoskeletal conditions
than has previously been possible. It also demonstrated con-
sistency between three similar meta-analyses of clinical trial
reports covering over 80,000 patients with these conditions.
Consistent differences between different drugs were seen,
principally fewer adverse event discontinuations with coxibs
than with NSAIDs.
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Etoricoxib versus NSAID (all trials) 17 39,881 1.0 0.7 1.5 (1.2 to 1.9)a 320 (200 to 720)c
Note that nonsteroidal anti-inflammatory drugs (NSAIDs) indicates traditional NSAIDs only. aStatistically significant difference in relative risk. 
bNumber needed to treat to prevent an event (NNTp). cNumber needed to cause an event (NNH). CI, confidence interval.
Table 2 (Continued)
Analysis of patients with adverse events and discontinuations
Figure 4
Gastrointestinal discontinuations with etoricoxib and placebo in individ- ual trials Gastrointestinal discontinuations with etoricoxib and placebo in individ-
ual trials. Yellow symbols are trials lasting 4 to 12 weeks; red symbols 
are trials of longer duration. GI, gastrointestinal; NSAID, nonsteroidal 
anti-inflammatory drug.
Figure 5
Gastrointestinal AE discontinuations with different therapies in three  analyses of trials lasting 4 to 12 weeks Gastrointestinal AE discontinuations with different therapies in three 
analyses of trials lasting 4 to 12 weeks. AE, adverse event; NSAID, 
nonsteroidal anti-inflammatory drug.Arthritis Research & Therapy    Vol 10 No 3    Moore et al.
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